Impactful innovation

Supported by significant continuous investment in research infrastructure and systems, we are driven to make discoveries and find innovations that enhance patient treatment and care. The global influence of our work is greatly enriched through our international academic and industry partnerships across a number of critical research areas.

Innovative breakthroughs in these areas include InnovoSep, a therapeutic with the potential to stop sepsis-causing microorganisms from triggering organ damage in the early stages of the condition. According to the World Health Organisation, sepsis is estimated to affect hundreds of millions of patients globally each year. This promising new sepsis treatment, currently under development by researchers at RCSI, could lead to lifesaving improvements in healthcare and patient outcomes.

Global innovations in healthcare

To support our breakthrough innovations in healthcare, our dedicated Innovation team works to assess and verify commercial potential, as well as to build meaningful engagement and collaboration with industry and other healthcare partners. We are the academic partner to seven hospitals in the RCSI Hospital Group and we are the founding partner in multiple national research centres.

Working with industry

We facilitate and build partnerships with industry through matching industry needs to our researchers’ capabilities and by providing funding support and state-of-the-art surgical simulation, medical training facilities and research infrastructure. Our successes in delivering efficient project set-up, implementation and knowledge transfer have led to healthcare improvements in areas such as vascular medicine and cancer research.

This is exemplified by partnerships with organisations like LEO Pharma, a collaboration initiated to gain a deeper understanding of the role of blood clotting protein in the spread of breast cancer. With clot formation as the second leading cause of death for all cancer patients, this research and the support of our industry partner could prove vital in transforming the lives of patients and families effected by breast cancer. We facilitate and build partnerships with industry through matching industry needs to our researchers’ capabilities and by providing funding support and state-of-the-art surgical simulation, medical training facilities and research infrastructure.

Learn more about how we work with industry partners.

RCSI researcher working under hood

Technologies for licence

We assist our researchers in commercialising their research outputs through the licensing and co-development of intellectual property to both established businesses and start-up companies. These partnerships and activities are vitally important to the creation of new advances in diagnosticsmedical devices and therapeutics.

Our commercialisation successes include the breast cancer cell line created by RCSI researchers and licensed out to Ximbio, a part of the technology transfer office at Cancer Research UK. The cell line is specifically designed as a research tool to investigate the biological pathways associated with cancer treatment resistance and, because of the support of our Innovation team in IP licensing, now has the potential to reach a global network of cancer specialists and accelerate impactful research into cancer treatment. 

Investors and entrepreneurs

We support partnerships with investors and entrepreneurs aimed at creating spin-out or high potential start-up companies based on RCSI intellectual property or aligned with our research focus. Connecting our researchers with potential partners is vitally important to delivering on our mission to improve human health and patient outcomes on a global scale. Proof of our overall success is in the rapid growth of our industry collaboration and commercialisation activity. Our industry collaborations have rapidly increased since 2014, with a two-fold increase in inventions identified by our researchers and a six-fold increase in commercialisation activity.

10% of research income now comes from industry sources, demonstrating the capacity of our researchers to attract industry funding and maximising the opportunity for their work to impact patient treatment and care.